» Articles » PMID: 26848930

Where There's Smoke, There's Fire? Significance of Atrial Fibrillation in Young Patients

Overview
Journal Clin Cardiol
Date 2016 Feb 6
PMID 26848930
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Atrial fibrillation (AF), a disease of the elderly, occasionally occurs at younger age. Pathophysiology of AF in younger patients is diverse, including channelopathies and cardiomyopathies. Data on the significance and complications of AF in young patients are scarce.

Hypothesis: Atrial fibrillation is the first manifestation of cardiovascular disease (CVD) in young patients.

Methods: From 11 888 patients in a university hospital database, patients age ≤35 years were identified. A composite of stroke/transient ischemic attack, thromboembolic events, major bleeding, and death was the primary endpoint. Stroke/transient ischemic attack, thromboembolic events, major bleeding, death, AF during follow-up, diagnosis of arrhythmia other than AF, and new diagnosis of any CVD were secondary endpoints. Endpoints were compared between patients with and without comorbidities.

Results: We identified 124 patients (29.1± 5 years). Of those, 84 were followed over 48.4 ± 39.8 months. Comorbidities were present in 40.5%. Incidence of the primary endpoint was not different between the groups. Arrhythmias other than AF were more common in patients without comorbidities (36% vs 14.7%; P = 0.032). A supraventricular tachycardia (SVT) was found in 57.1% of patients who underwent electrophysiological testing and was treated with catheter ablation. None of those patients had AF during follow-up.

Conclusions: Atrial fibrillation occurs in young patients with and without structural heart disease. Young AF patients without comorbidities rarely develop CVD during the first years after diagnosis. Yet, an SVT is found in a high proportion of young AF patients; AF may be first manifestation of SVT. Therefore, young patients should undergo further evaluation for SVT.

Citing Articles

The higher recurrence rate after catheter ablation in younger patients with atrial fibrillation suggesting different pathophysiology.

Ahn H, Cha M, Lee E, Lee S, Choi E, Han S J Interv Card Electrophysiol. 2023; 66(7):1609-1619.

PMID: 36648614 DOI: 10.1007/s10840-022-01461-0.


Atrial fibrillation as a presenting symptom of Cardiac Sarcoid.

Hussain A, Yiu A, Okonkwo U, OShea J J Atr Fibrillation. 2021; 14(1):20200484.

PMID: 34950363 PMC: 8691322. DOI: 10.4022/jafib.20200484.

References
1.
Maron B, Casey S, Poliac L, Gohman T, Almquist A, Aeppli D . Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999; 281(7):650-5. DOI: 10.1001/jama.281.7.650. View

2.
Hayashi H, Wang C, Miyauchi Y, Omichi C, Pak H, Zhou S . Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2002; 13(8):801-8. DOI: 10.1046/j.1540-8167.2002.00801.x. View

3.
Gilligan D, Zakaib J, Fuller I, Shepard R, Dan D, Wood M . Long-term outcome of patients after successful radiofrequency ablation for typical atrial flutter. Pacing Clin Electrophysiol. 2003; 26(1 Pt 1):53-8. DOI: 10.1046/j.1460-9592.2003.00150.x. View

4.
Mestroni L . Genomic medicine and atrial fibrillation. J Am Coll Cardiol. 2003; 41(12):2193-6. DOI: 10.1016/s0735-1097(03)00459-5. View

5.
Lin P, Lee S, Su C, Wei Y . Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation. Free Radic Biol Med. 2003; 35(10):1310-8. DOI: 10.1016/j.freeradbiomed.2003.07.002. View